Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 21
2023
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.01%
|
$1,962
$327.51 P/Share
|
|
Feb 17
2023
|
Johna Norton EVP, Global Quality |
SELL
Bona fide gift
|
Direct |
500
-1.47%
|
-
|
|
Feb 16
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,314
-9.99%
|
$440,190
$335.01 P/Share
|
|
Feb 16
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
2,785
+17.47%
|
-
|
|
Feb 13
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Open market or private sale
|
Direct |
2,500
-4.14%
|
$865,000
$346.47 P/Share
|
|
Feb 10
2023
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Grant, award, or other acquisition
|
Direct |
1,350
+9.42%
|
$465,750
$345.12 P/Share
|
|
Feb 10
2023
|
Donald A Zakrowski SVP, Finance, & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,904
+20.96%
|
$656,880
$345.12 P/Share
|
|
Feb 10
2023
|
Alonzo Weems EVP, ERM & CECO |
BUY
Grant, award, or other acquisition
|
Direct |
2,422
+21.35%
|
$835,590
$345.12 P/Share
|
|
Feb 10
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Open market or private sale
|
Direct |
2,500
-3.97%
|
$855,000
$342.76 P/Share
|
|
Feb 10
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Grant, award, or other acquisition
|
Direct |
8,562
+11.98%
|
$2,953,890
$345.12 P/Share
|
|
Feb 10
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
18,388
+14.83%
|
$6,343,860
$345.12 P/Share
|
|
Feb 10
2023
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
2,407
+18.83%
|
$830,415
$345.12 P/Share
|
|
Feb 10
2023
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
56,208
+11.24%
|
$19,391,760
$345.12 P/Share
|
|
Feb 10
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Grant, award, or other acquisition
|
Direct |
8,023
+16.96%
|
$2,767,935
$345.12 P/Share
|
|
Feb 10
2023
|
Johna Norton EVP, Global Quality |
BUY
Grant, award, or other acquisition
|
Direct |
2,507
+6.88%
|
$864,915
$345.12 P/Share
|
|
Feb 10
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Grant, award, or other acquisition
|
Direct |
3,681
+10.42%
|
$1,269,945
$345.12 P/Share
|
|
Feb 10
2023
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
BUY
Grant, award, or other acquisition
|
Direct |
7,886
+15.52%
|
$2,720,670
$345.12 P/Share
|
|
Feb 10
2023
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,204
+16.78%
|
$1,795,380
$345.12 P/Share
|
|
Feb 10
2023
|
Anat Ashkenazi EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,693
+14.94%
|
$2,309,085
$345.12 P/Share
|
|
Feb 10
2023
|
Eric Dozier EVP, Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,820
+23.51%
|
$627,900
$345.12 P/Share
|
|
Feb 10
2023
|
Anat Hakim EVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
9,072
+29.02%
|
$3,129,840
$345.12 P/Share
|
|
Feb 08
2023
|
David A Ricks President, Chair, and CEO |
SELL
Bona fide gift
|
Direct |
4,200
-1.07%
|
-
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
7,035
-7.47%
|
$2,420,040
$344.15 P/Share
|
|
Feb 01
2023
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
15,675
+14.26%
|
-
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
3,252
-5.64%
|
$1,118,688
$344.15 P/Share
|
|
Feb 01
2023
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
7,264
+11.2%
|
-
|
|
Feb 01
2023
|
Johna Norton EVP, Global Quality |
SELL
Payment of exercise price or tax liability
|
Direct |
941
-2.91%
|
$323,704
$344.15 P/Share
|
|
Feb 01
2023
|
Johna Norton EVP, Global Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
2,102
+6.1%
|
-
|
|
Feb 01
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,438
-4.89%
|
$494,672
$344.15 P/Share
|
|
Feb 01
2023
|
Leigh Ann Pusey EVP, Corp. Affairs & Comm. |
BUY
Exercise of conversion of derivative security
|
Direct |
3,154
+9.69%
|
-
|
|
Feb 01
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
SELL
Payment of exercise price or tax liability
|
Direct |
2,935
-8.58%
|
$1,009,640
$344.15 P/Share
|
|
Feb 01
2023
|
Michael B Mason EVP & Pres., Lilly Diabetes |
BUY
Exercise of conversion of derivative security
|
Direct |
6,690
+16.36%
|
-
|
|
Feb 01
2023
|
Anat Hakim EVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
3,393
-20.55%
|
$1,167,192
$344.15 P/Share
|
|
Feb 01
2023
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,646
+31.65%
|
-
|
|
Feb 01
2023
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,997
-7.88%
|
$1,030,968
$344.15 P/Share
|
|
Feb 01
2023
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
BUY
Exercise of conversion of derivative security
|
Direct |
6,690
+14.95%
|
-
|
|
Feb 01
2023
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,359
-5.17%
|
$7,347,496
$344.15 P/Share
|
|
Feb 01
2023
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
47,786
+10.37%
|
-
|
|
Jan 17
2023
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
14
+0.87%
|
$4,998
$357.74 P/Share
|
|
Jan 17
2023
|
Jackson P Tai Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.01%
|
$2,142
$357.74 P/Share
|
|
Jan 17
2023
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+4.51%
|
$9,996
$357.74 P/Share
|
|
Jan 17
2023
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
40
+0.27%
|
$14,280
$357.74 P/Share
|
|
Jan 17
2023
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27
+1.34%
|
$9,639
$357.74 P/Share
|
|
Jan 17
2023
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+0.04%
|
$9,996
$357.74 P/Share
|
|
Jan 17
2023
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+0.06%
|
$11,424
$357.74 P/Share
|
|
Dec 19
2022
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
32
+0.06%
|
$11,424
$357.78 P/Share
|
|
Dec 19
2022
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+0.04%
|
$9,996
$357.78 P/Share
|
|
Dec 19
2022
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
28
+4.72%
|
$9,996
$357.78 P/Share
|
|
Dec 19
2022
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
27
+1.36%
|
$9,639
$357.78 P/Share
|
|
Dec 19
2022
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
39
+0.26%
|
$13,923
$357.78 P/Share
|